A Notoriously Slow, Expensive Process
Traditional drug discovery and development is notoriously slow and expensive, often taking over a decade and enormous financial investment from initial target identification to an approved medication, with the vast majority of candidate compounds failing somewhere along this long pipeline. Artificial intelligence is being applied across multiple stages of this process with genuine potential to compress timelines and reduce the staggering failure rate that makes drug development so costly.
Where AI Is Making a Difference
AI systems now assist in identifying promising biological targets for disease, predicting the three-dimensional structure of proteins with a speed and accuracy that previously required years of laboratory work, and designing and screening candidate molecules computationally before committing to expensive laboratory synthesis and testing. These applications compress stages that traditionally required extensive trial-and-error laboratory work into faster, more targeted computational processes.
Realistic Expectations for Impact
While AI has already demonstrably accelerated specific steps in drug discovery, the overall drug development timeline remains long because clinical trials — testing safety and efficacy in humans — cannot be shortened by computation alone and remain bound by biological and ethical realities of human testing. AI compression of the early discovery phases is genuinely valuable, but transforming the entire pipeline, including clinical testing, will take longer to fully realize. Facilities can source lab supplies and pharmacy supplies from our catalog.
